TY  - JOUR
T1  - Cardiovascular Safety in the Treatment of Chronic Rheumatic Pathologies
A1  - Tamerlan Tulegenovich Zakaev
A1  - Medina Vakhaevna Bakrieva
A1  - Rabiyat Tazhutdinovna Alkhazova
A1  - Diana Borisovna Girkina
A1  - Anzhela Yunusovna Chagarova
A1  - Angelina Andreevna Polyanskaya
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2023
VL  - 12
IS  - 2
DO  - 10.51847/wXAjWjcJY7
SP  - 54
EP  - 57
N2  - According to statistics from the World Health Organization (WHO), from 9 to 45% of people are susceptible to diseases of the musculoskeletal system. In addition, about 3% of people can be classified as disabled due to their condition of bones and joints, and almost every one of this 3% will experience severe pain. To eliminate pain, doctors prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to these people. Within the framework of this article, the possibility of using NSAIDs in chronic inflammatory rheumatic pathologies was considered, and their effect on the human body was also considered. In a study of patients with severe psoriatic arthritis, it was found that prevention with methotrexate led to the least number of cases of cardiovascular diseases in comparison with other methods of prevention, including traditional treatment, phototherapy, and climatotherapy. It has also been suggested that the effect of inhibitors is a defense against tumor necrosis. The method of prevention of patients with severe forms of psoriatic arthritis can greatly affect the reduction in the number of cardiovascular diseases, as a result, local studies are needed to more accurately assess the cardiovascular safety and effectiveness of systemic therapy. 
UR  - https://ijpras.com/article/cardiovascular-safety-in-the-treatment-of-chronic-rheumatic-pathologies-gut2pxu83u5bh37
ER  -